HTG Molecular Diagnostics Inc (NASDAQ:HTGM) will post its quarterly earnings results after the market closes on Wednesday, March 22nd. Analysts expect HTG Molecular Diagnostics to post earnings of ($0.76) per share for the quarter.
Shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) opened at 2.14 on Tuesday. HTG Molecular Diagnostics Inc has a 12-month low of $1.20 and a 12-month high of $4.45. The company’s 50-day moving average is $2.11 and its 200-day moving average is $2.21. The company’s market capitalization is $15.12 million.
Separately, Zacks Investment Research lowered shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, January 17th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $5.25.
Your IP Address:
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.